Assessment of cardiovascular risk

Jump to navigation Jump to search

Atherosclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atherosclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Assessment of Cardiovascular Risk

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocadiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

ACC/AHA Guideline Recommendations

Assessment of cardiovascular risk

Secondary prevention

Case Studies

Case #1

Assessment of cardiovascular risk On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Assessment of cardiovascular risk

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Assessment of cardiovascular risk

CDC on Assessment of cardiovascular risk

Assessment of cardiovascular risk in the news

Blogs on Assessment of cardiovascular risk

Directions to Hospitals Treating Atherosclerosis

Risk calculators and risk factors for Assessment of cardiovascular risk

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk[1]

Summary of Recommendations for Risk Assessment of Cardiovascular Risk

Implementation of Risk Assessment Work Group Recommendations

Implementation of Risk Assessment Work Group Recommendations

Assessment of 10-Year Risk of a First Hard ASCVD Event

Class I
"1. The race- and sex-specific Pooled Cohort Equations* to predict 10-year risk of a first hard ASCVD event should be used in non-Hispanic African

Americans and non-Hispanic whites, 40–79 years of age.(Level of Evidence: B)"

Class IIb
"1. Assessment of 10-Year Risk of a First Hard ASCVD Event
  • Use of the sex-specific Pooled Cohort Equations for non-Hispanic whites may be considered for estimation of risk in patients from populations other than African Americans and non-Hispanic whites. (Level of Evidence: C)"

Use of Newer Risk Markers After Quantitative Risk Assessment

Class III†
"1.Routine measurement of CIMT is not recommended in clinical practice for risk assessment for a first ASCVD event. (Level of Evidence: B) "
Class IIb†
"1.If, after quantitative risk assessment, a risk-based treatment decision is uncertain, assessment of ≥1 of the followingdfamily history, hs-CRP, CAC score, or ABIdmay be considered to inform treatment decision making. (Level of Evidence: B)"

Long-Term Risk Assessment

Class IIa
"1. It is reasonable to assess traditional ASCVD risk factors‡ every 4–6 years in adults 20–79 years of age who are free from ASCVD and to estimate 10-year ASCVD risk every 4–6 years in adults 40–79 years of age who are free from ASCVD.(Level of Evidence: B)"
Class IIb
"3. Assessment of 30-year or lifetime ASCVD risk on the basis of traditional risk factorsz may be considered in adults 20–59 years of age who are free from ASCVD and are not at high short-term risk. (Level of Evidence: C)"


*Derived from the ARIC (Atherosclerosis Risk in Communities) study, Cardiovascular Health Study , CARDIA (Coronary Artery Risk Development in Young Adults) study , and Framingham original and offspring cohorts
†Based on new evidence reviewed during ACC/AHA update of evidence
‡Age, sex, total cholesterol, high-density lipoprotein cholesterol, systolic BP, use of antihypertensive therapy, diabetes, and current smoking. ABI indicates ankle-brachial index; ACC, American College of Cardiology; AHA, American Heart Association; ApoB, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CAC, coronary artery calcium; CIMT, carotid intima-media thickness; CKD, chronic kidney disease; COR, Class of Recommendation; CQ, critical question, ES, evidence statement; hs-CRP, high-sensitivity C-reactive protein; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute; and d, not applicable.

References


Template:WikiDoc Sources